Loading
A phase 2 trial of Durvalumab and Gemcitabine in advanced solid tumours, run by AstraZeneca, active and no longer recruiting.
Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours is a phase 2 interventional study registered as NCT04999969 by AstraZeneca, with 126 participants enrolled, started 2021-12-10 and due to reach its primary completion in 2024-10-07. Interventions recorded: AZD0171, Durvalumab, Gemcitabine and Nab-paclitaxel. Results have been posted on the registry.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
126 enrolled.
80% CI 47.79 to 59.50; Figures from the ClinicalTrials.gov results section (first posted 2025-11-26), not from a publication
Source80% CI 6.801 to 7.918; Figures from the ClinicalTrials.gov results section (first posted 2025-11-26), not from a publication
Source80% CI 29.30 to 40.91; Figures from the ClinicalTrials.gov results section (first posted 2025-11-26), not from a publication
SourceShares Durvalumab, AstraZeneca, Metastatic cancer (cancer that has spread), Immune checkpoint inhibitors and the tag pipeline.
Shares Durvalumab, AstraZeneca, Metastatic cancer (cancer that has spread), Immune checkpoint inhibitors and the tag pipeline.
Shares Durvalumab, AstraZeneca, Immune checkpoint inhibitors and the tag pipeline.
Shares Durvalumab, Gemcitabine, AstraZeneca, Immune checkpoint inhibitors and the tag pipeline.
Shares Durvalumab, AstraZeneca, Immune checkpoint inhibitors and the tag pipeline.
Shares Durvalumab, AstraZeneca, Immune checkpoint inhibitors and the tag pipeline.
Shares Durvalumab, AstraZeneca, Metastatic cancer (cancer that has spread), Immune checkpoint inhibitors and the tag pipeline.
Shares Durvalumab, Gemcitabine, AstraZeneca, Immune checkpoint inhibitors and the tag pipeline.